Orpheris enrolls first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

Orpheris enrolls first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

Source: 
Pharmaceutical Business Review
snippet: 

Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.